Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30526816 | 1.00 | MAPT (0.56) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL9774731 | 0.84 | MAOB (0.61) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL12557899 | 0.82 | MAOB (0.46) | MAPTNPC1RAB9ASMN1; SMN2ALOX15 | |
| SCHEMBL31658444 | 0.82 | MAP4K4 (0.52) | MAOBCYP1A2 | |
| SCHEMBL29261601 | 0.79 | SMPD3 (0.45) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL30526607 | 0.79 | RAB9A (0.60) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL32686155 | 0.75 | ALDH1A1 (0.50) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL15079656 | 0.75 | SCD (0.49) | MAPTNPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL1979808 | 0.74 | GAA (0.42) | MAPTNPC1RAB9ASMN1; SMN2PIK3CA | |
| SCHEMBL1981584 | 0.73 | GAA (0.41) | MAPTNPC1RAB9ASMN1; SMN2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763998-B1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2016-04-27 | — | — | EP | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| WO-2013091502-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | MAP3K15, MAP3K1, MAP3K5 | MAPT 2207/4885NPC1 3037/4885RAB9A 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.